Marshall Wace’s BioLineRX BLRX Stock Holding History

Marshall Wace’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-363	Closed	-$29K	–	3367
2021 Q4	$29K	Buy	+363	New	+$37.8K	﹤0.01%	3663

Other funds holding BLRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $6.15B AUM 22.62% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's BLRX Position: Q1 2022 in Review

Marshall Wace sold out of BioLineRX (BLRX) in Q1 2022, closing a stake of 363 shares — an estimated $29K sold.

Marshall Wace first reported a position in BLRX in Q4 2021 and held it in 1 quarter. The position peaked at $29K in Q4 2021. 26 funds tracked by Wall St. Rank hold BLRX as of Q1 2022.

Marshall Wace reported no remaining BioLineRX position as of Q1 2022 after selling out during the quarter.
Marshall Wace sold 363 BioLineRX shares in Q1 2022, an estimated $29K.
Marshall Wace first reported a position in BioLineRX in Q4 2021 and held it in 1 quarter.
Marshall Wace's BioLineRX position peaked at $29K in Q4 2021.
26 funds tracked by Wall St. Rank held BioLineRX as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.